BETA
Developer of the investigational PerQdisc lumbar nucleus replacement system.
Spinal Stabilization Technologies develops PerQdisc, a silicone-based implant formed in situ to replace the nucleus pulposus of a lumbar disc. The design aims to preserve motion and restore aspects of disc mechanics for selected patients with chronic discogenic low-back pain.
The company dates its foundation to 2010 and identifies Mark Novotny as CEO. Its published corporate contact is in Kilkenny, Ireland. This corporate address is distinguished from U.S. clinical and business activity rather than treating the company as exclusively U.S.-headquartered.
Current company labeling states that PerQdisc is investigational and not approved for sale in the United States or regions accepting the CE Mark. Earlier feasibility research and ongoing trial programs are evidence-development activities. Neither a study authorization nor a proposed motion-preservation benefit establishes commercial availability or comparative clinical efficacy.
PerQdisc remains investigational and is not FDA-approved or available for U.S. sale according to the company. Its clinical studies concern evidence generation for nucleus replacement; no matching published FDA marketing decision was found. [7][11][8][1]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [5][3]
Latest recorded source review: 2026-10-20.
No routinely marketed devices established in the reviewed scope.
The company describes PerQdisc trial programs including feasibility and later clinical studies. Recruitment status, regulatory permissions and endpoints should be checked at the specific study level. [9]
In-situ formed silicone implant intended to replace the lumbar nucleus while preserving motion. [7][11][9]
Investigational / in developmentInvestigational only; not commercially available.
Accessed 10/20/2026